Skip to content

A Study on the Authenticity Identification of Nocturnal Hypertension Diagnosed by Ambulatory Blood Pressure: A Randomized cross-controlled Trial Based on Multimodal Sleep Monitoring

A Study on the Authenticity Identification of Nocturnal Hypertension Diagnosed by Ambulatory Blood Pressure: A Randomized cross-controlled Trial Based on Multimodal Sleep Monitoring

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118463
Enrollment
Unknown
Registered
2026-02-05
Start date
2026-03-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nocturnal Hypertension

Interventions

AB group:Phase 1: Receive Intervention A (Zopiclone 1mg on the right, ABPM sleep monitoring)
Washout period: -2 days (natural state, avoid using sedatives)
Phase 2: Receive Intervention B (ABPM sleep monitoring, placebo)
BA group:Stage 1: Receive Intervention B (ABPM, sleep monitoring, placebo)
Washout period: 2 days (natural state, avoid using sedatives)
Stage 2: Receive Intervention A (right-side Zopiclone 1mg, ABPM, sleep monitoring)

Sponsors

Daping Hospital, Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Nighttime blood pressure >= 120/70 mmHg on 24-hour ambulatory blood pressure monitoring; 3. Able to independently complete ABPM and PSG monitoring, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe insomnia (PSQI >16) or long-term use of benzodiazepines/sedatives; 2. Sleep apnea requiring CPAP; 3. Secondary hypertension (e.g., renal artery stenosis, primary aldosteronism, etc.); 4. Thyroid dysfunction (TSH exceeding twice the normal range); 5. Acute cardiovascular or cerebrovascular events (myocardial infarction, stroke, or unstable angina within the past 6 months); 6. Severe heart failure (NYHA class III-IV) or arrhythmia; 7. Acute exacerbation of chronic obstructive pulmonary disease, decompensated respiratory failure, or myasthenia gravis patients; 8. Active hepatitis or significant liver dysfunction (ALT or AST >2 ULN, TBIL >2 ULN, or Child-Pugh score >= class B); 9. Renal impairment (eGFR =3 time zones in the past month; 15. Pregnant or breastfeeding women; 16. Severe psychiatric disorders (PHQ-9 >=15) or cognitive impairment (MMSE <24); 17. Participants who have received other investigational drugs or medical device treatments within the month prior to screening or within 5 half-lives (whichever is longer).

Design outcomes

Primary

MeasureTime frame
Ambulatory Blood Pressure Monitoring;Polysomnography;

Countries

China

Contacts

Public ContactChunyu Zeng

Department of Cardiology, Daping Hospital, Army Medical University, Chongqing, P.R. China.

chunyuzeng01@163.com+86 139 8362 4369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026